Kagawa, Yoshinori http://orcid.org/0000-0001-6876-4507
Smith, J. Joshua http://orcid.org/0000-0003-2538-5456
Fokas, Emmanouil http://orcid.org/0000-0003-1601-6165
Watanabe, Jun http://orcid.org/0000-0002-7187-3664
Cercek, Andrea
Greten, Florian R. http://orcid.org/0000-0002-3928-6080
Bando, Hideaki http://orcid.org/0000-0001-5041-2765
Shi, Qian
Garcia-Aguilar, Julio http://orcid.org/0000-0003-2451-0948
Romesser, Paul B. http://orcid.org/0000-0001-8268-2903
Horvat, Natally
Sanoff, Hanna
Hall, William
Kato, Takeshi
Rödel, Claus
Dasari, Arvind http://orcid.org/0000-0001-5271-9744
Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Article History
Accepted: 26 January 2024
First Online: 14 March 2024
Competing interests
: Y.K. received honoraria for lectures from Johnson & Johnson, Intuitive Surgical Medtronic, Eli Lilly, Chugai, Ono, MSD, Merck Biopharma and Takeda, and received research funding from Ono and Takeda. J.J.S. received travel support for fellow education from Intuitive Surgical (2015). He served as a clinical adviser for Guardant Health (2019) and for Foundation Medicine (2022), and served as a consultant and speaker for Johnson & Johnson (2022). He also serves as a clinical advisor and consultant for GSK (2023). J.W. received honoraria for lectures from Johnson & Johnson, Medtronic, Eli Lilly and Takeda, and received research funding from Medtronic, Terumo, Amco and Stryker Japan outside the submitted work. A.C. is on the advisory board for Bayer, Merck, GSK, Seagen, Roche, Pfizer and Illumina, has received research funding from Seagen and GSK, and has equity in Haystack Oncology. H.B. reports research funding from Ono Pharmaceutical and honoraria from Taiho Pharmaceutical and Eli Lilly, Japan. Q.S. reports a consulting/advisory role from Yiviva Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Hoosier Cancer Research Network, Kronos Bio and Mirati Therapeutics Inc., a personal honorarium/speaker role from Chugai Pharmaceutical Co., Ltd. and research funds to their institution from Celgene/BMS, Roche/Genentech, Janssen and Novartis. J.G.-A. has relevant disclosures as noted: Johnson & Johnson (honorarium), Medtronic (honorarium) and Intuitive Surgical (honorarium, stock). P.B.R. is a consultant for Natera. N.H. received a lecture fee from Bayer (2022), served as a consultant for Guerbet (2023) and received travel support for a radiology meeting from Guerbet (2023). H.S. has received research funding from Amgen, AstraZeneca, BioMed Valley Discoveries, Bristol Myers Squibb, Exelixis, Pfizer, Rgenix and F Hoffman LaRoche. W.H. is a consultant for Aktis oncology outside of the submitted work, Medical College of Wisconsin holds a provisional patent, inventors William A. Hall and Eric Paulson, number 63/483,252, status is provisional, no aspect of the manuscript is covered in the patent application, the patent is outside of the submitted work. W.H. serves on the clinical steering committee for the Atlantic MR Linac consortium sponsored by Elekta AB and is the pancreatic site lead for this research consortium. Elekta AB provides institutional research and travel support to the Medical College of Wisconsin Department of Radiation Oncology. T.K. reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical Company Limited, ONO Pharmaceutical Co., Eli Lilly and Company and Yakult Honsha Company and research funding from Taiho Pharmaceutical. A.D. received consulting fees from HUTCHMED, Takeda, Illumina, Personalis, AAA/Novartis, Ipsen and Sirtex, and research funding (institutional) from HUTCHMED, Xencor, Guardant Health, Eisai, Natera, Enterome and Taiho. T.Y. reports research funding from Taiho, Ono, Chugai, Amgen, MSD, Daiichi-Sankyo, Eisai, FALCO biosystems, Genomedia, Molecular Health, Nippon Boehringer Ingelheim, Pfizer, Roche Diagnostics, Sysmex and Sanofi; honoraria from Bayer, Chugai, Merck Biopharma, MSD, Ono and Takeda; consulting role from Sumitomo Corp.; and consulting fee from Sumitomo Corp. The other authors declare no competing interests.